Racial and ethnic disparities in clinical trials for pediatric obesity

Catherine G Coughlin1, Emilie S Zoltick2, Fatima Cody Stanford3

  • 1Division of Emergency Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.

PubMed

Insights

Historically marginalized racial and ethnic groups, except for Black and Hispanic children, were underrepresented in pediatric obesity clinical trials. Improved diversity and race/ethnicity data reporting are crucial for equitable research.

Area of Science:

  • Clinical research
  • Pediatric health
  • Health equity

Background:

  • Pediatric obesity is a significant public health concern.
  • Clinical trials are essential for developing effective obesity treatments.
  • Ensuring diverse participant representation is critical for generalizability and equity.

Purpose of the Study:

  • To assess the representation of historically marginalized racial and ethnic groups in U.S. pediatric obesity clinical trials.
  • To identify disparities in enrollment compared to disease prevalence.
  • To highlight gaps in race and ethnicity data collection and reporting.

Main Methods:

  • Cross-sectional analysis of pediatric obesity trials registered in ClinicalTrials.gov.
  • Included trials completed between January 2013 and August 2023 in the United States.
  • Calculated enrollment-prevalence disparity (EPD) to quantify underrepresentation.

Main Results:

  • 260 trials met eligibility; 49.2% reported race/ethnicity data.
  • White, Hispanic, and Black children's enrollment generally reflected disease burden.
  • Asian, American Indian/Alaska Native, and Native Hawaiian/Pacific Islander children were significantly underrepresented (EPD < 0).

Conclusions:

  • Significant underrepresentation of several marginalized groups in pediatric obesity trials indicates a need for improved participant diversity.
  • Substantial gaps exist in the documentation and reporting of race and ethnicity information.
  • Concerted efforts are necessary to enhance data collection and ensure adequate representation in clinical trials.
Abstract

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
99
Stereotypes, Prejudice, and Discrimination02:55

Stereotypes, Prejudice, and Discrimination

Humans are very diverse and although we share many similarities, we also have many differences. The social groups we belong to help form our identities (Tajfel, 1974). These differences may be difficult for some people to reconcile, which may lead to prejudice toward people who are different. Prejudice is a negative attitude and feeling toward an individual based solely on one’s membership in a particular social group (Allport, 1954; Brown, 2010). Prejudice is common against people who...
90.1K
Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.3K